Annual Cancer Symposium - 2010 Scientific Program - Sunday Sessions
Order Session DVDs HERE while supplies last.
Go To: Wednesday's Sessions | Thursday's Sessions | Friday's Sessions | Saturday's Sessions | Sunday's Sessions | All Posters
Breakfast Symposium
Optimizing Outcomes in Gastrointestinal Neuroendocrine Tumors
7:00 – 8:45 am Sunday Room 220 • America’s Center
Partially supported by educational grants from Ipsen and MDS Nordion
Moderators: Martin D. McCarter, MD* and Clifford Cho, MD**
*Disclosure: Consultant: Covidien; Speaker: Institute for Medical Education and Research **Disclosure: None
7:00 am Pre-operative Assessment and Staging of Neuroendocrine Tumors of the Gastrointestinal Tract: What is Helpful?
Herbert Chen, MD
ViceChair, Department of Surgery Professor of Surgery Chief, Endocrine Surgery University of Wisconsin Leader, Endocrine Cancer Disease Group University of Wisconsin Carbone Cancer Center Madison, WI
Disclosure: Consultant, Advisory Board, Research Grant: Novartis Speaker: Pfizer Advisory Board: Ipsen
7:20 am Surgical Treatment of Primary Gastrointestinal Neuroendocrine Tumors
George Poultsides, MD
Assistant Professor of Surgery Stanford University Medical Center Stanford, CA
Disclosure: None
7:40 am Optimizing Outcomes in Metastatic
Gastrointestinal Neuroendocrine Tumors
Robert C. G. Martin, II, MD, PhD
Associate Professor of Surgery Director, Division of Surgical Oncology University of Louisville Louisville, KY
Disclosure: Consultant: Biocompatibles, Covidien; Research Grant: Boston Scientific (OffLabel Use of Treatments)
8:00 am Targeted Molecular Therapy for Gastrointestinal Neuroendocrine Tumors: Do We Have a New Paradigm?
Chandrajit P. Raut, MD, MSc
Assistant Professor of Surgery Harvard Medical School Associate Surgeon, DanaFarber/Brigham and Women’s Cancer Center Boston, MA
Disclosure: Advisory Board, Honorarium: Novartis
8:20 am Panel Discussion/Questions
Objectives: At the conclusion of this session, participants should be able to: a) describe appropriate preoperative studies for patients with gastrointestinal neuroendocrine tumors; b) determine differences in tumor biology of neuroendocrine tumors from different areas of the gastrointestinal tract; c) identify the principals and goals of managing primary resectable neuroendocrine tumors; d) discuss the advantages and disadvantages of minimally invasive approaches to neuroendocrine tumors; e) identify the principals and goals of managing metastatic neuroendocrine tumors; f) describe various approaches to neuroendocrine tumor debulking; and g) discuss the molecular basis for targeted therapeutics in neuroendocrine tumors; and h) discuss the role of emerging molecular targeted agents in contemporary management of neuroendocrine tumors.
Disparities Committee Presents
Contemporary Issues and Controversies in Cancer Disparities
9:00 – 11:00 am Sunday Room 221-228 • America’s Center
Partially supported by educational grants from AstraZeneca, LP, and Eli Lilly & Company
Moderator: Hank C. Hill, MD
Disclosure: Speaker: Myriad Genetic Laboratory, Inc.
9:05 am Health Care Reform Legislation: How It Will/Will Not Affect Cancer Disparities
Otis W. Brawley, MD
Chief Medical Officer American Cancer Society Professor of Hematology, Oncology, and Epidemiology Emory University Atlanta, GA
Disclosure: None
9:30 am Genotyping and Ancestry Informative Markers as a Disparities Research Tool
Rick Kittles, PhD
Associate Professor Department of Medicine, Section of Genetic Medicine University of Chicago Chicago, IL
Disclosure: None
9:55 am Disparities and Cancer Clinical Trials
John H. Stewart, IV, MD
Assistant Professor of Surgery Wake Forest University School of Medicine Department of Surgery, Surgical Oncology Service WinstonSalem, NC
Disclosure: None
10:20 am International Partnerships as a Disparities
Research Tool
Lisa A. Newman, MD, MPH
Director, Breast Care Center Professor of Surgery University of Michigan Comprehensive Cancer Center Ann Arbor, MI
Disclosure: None
10:45 am Panel Discussion/Questions
Objectives: At the conclusion of this session, participants should be able to: a) discuss current options for health care reform legislation; b) describe the technology of genotyping for Ancestry Informative Markers; c) examine disparities in clinic trial accrual; and d) recognize international variation in cancer burden.
11:00 am Adjourn
Go To: Wednesday's Sessions | Thursday's Sessions | Friday's Sessions | Saturday's Sessions | Sunday's Sessions | All Posters
Order Session DVDs HERE while supplies last.